INS and cancer: The potential for Mendelian randomization is apparent from recent publications on genes that influence obesity and adenocarcinoma of the esophagus [31], high fasting insulin levels and endometrial cancer risk [32], vitamin D genes and both all-cause and cancer-specific mortality [33], and also for cardiovascular disease and lipid levels [34–36].